Pipeline

Building a Pipeline with a Focus on Immune Checkpoint and Ubiquitin Proteasome Inhibitors

Ensemble is focused on the discovery and development of breakthrough small molecule therapies for patients with cancer and other serious diseases. We are leveraging our proprietary drug discovery platform  to develop novel small molecule therapies that drug well-validated, challenging disease targets that have been intractable to regular small molecules or inaccessible to antibodies. Using our biological expertise within the cancer therapeutic area, we have focused our resources on targets within the immune checkpoint and ubiquitin proteasome inhibitor class, as the main focus for our drug discovery work. Our growing pipeline of small molecule therapies expands the boundaries of traditional therapeutics to address these important intra- and extracellular disease targets.

Pipeline